Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Open accessThe DOI matches its Crossref record; 131 of the 136 references it cites were found in a registry or an index.
Abstract
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Mechanisms of action for human topoisomerases. (A) Topoisomerase IA binds to DNA at a particular binding site, and then claves one strand, forming a transient 5′-phosphotyrosyl bond. The other DNA strand is transferred through the resultant break, allowing DNA to relax. Religation ends the process. (B) Toposiomerase IB works in a controlled rotation mechanism and in contrast to type IA enzymes forms a 3′-phosphotyrosyl bond with a DNA molecule. Both type I (A&B) topoisomerases do not require ATP hydrolysis as a source of energy. (C) Topoisomerase II binds to both ends of the DNA molecule, forms a double-strand break, and passes a segment of dsDNA through. This reaction is ATP-dependent [19].](https://figures.cochat.ai/paper-figures/7f178116e98944b58d61966403e83683/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-1.jpg)


![Figure 4 Mechanisms of cell death induced by irinotecan. The ternary irinotecan–topoisomerase I–nicked DNA complex with topoisomerase I (Topo I) inhibitor (SN-38) disables religation of the nicked strand and prevents topoisomerase release. Collision of the formed complex with advancing replication forks results in the formation of double-strand breaks (DSBs). This is followed by DNA damage response (DDR) signaling and TP53-induced gene expression of pro-apoptotic genes such as apoptosis regulator (BAX), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), or p53 up-regulated modulator of apoptosis (PUMA). Furthermore, down-regulation of the Bcl-2-like protein 1 isoform protein (BCL-xL) protein allows BAX and Bcl-2 homologous antagonist (BAK) embedding into the mitochondrial membrane and the formation of pores that allow the release of cytochrome C (cytC) from mitochondria and the subsequent formation of apoptosome with apoptotic protease-activating factor 1 (APAF-1) protein and procaspase-9. The activation of procaspase to caspase 9 (Casp-9) results in proteolytic cleavage and the conversion of procaspase 3 into active caspase 3 (Casp-3), which executes apoptosis [37,38,44,49,51].](https://figures.cochat.ai/paper-figures/e0271a41931a4560ab503b6a9b0123a1/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-4.jpg)
![Figure 5 Overview of irinotecan metabolism. CPT-11 is a prodrug that is converted to active metabolite ethyl-10-hydroxy-camptothecin (SN-38) by liver carboxylesterase converting enzymes (CES1/2) and is then transported to the liver by 1B1 polypeptide (OATP1B1) and inactivated by microsomal uridine 5′-diphospho-glucuronosyltransferase enzymes (UGTs): UGT1A1 and UGT1A9. Irinotecan is transported to bile by a group of the ATP-binding cassette transporters (ABC transporters): ABCB1, ABCC1, ABCC2, and ABCG2. Irinotecan is efficiently metabolized by cytochrome P450 enzymes: CYP3A4 and CYP3A5. This results in the generation of less active metabolites APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-amino-1-piperidino] carbonyloxycamptothecin). NPC (but not APC) can be further converted to SN-38 by CES1, and CES2 gut microbiota may also participate in irinotecan metabolism by the production of β-glucuronidase, which catalyzes the breakdown of SN-38G to SN-38. The inhibition of topoisomerase I (TOP1) results in DNA damage, replication fork arrest, and apoptotic cell death [53,54,55,56,57,58,59,60,61,62].](https://figures.cochat.ai/paper-figures/5036a4be7c55479baa6b8b63ea3ebd23/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Irinotecan (IRI) is a chemotherapeutic agent that inhibits topoisomerase I activity, which in turn inhibits both DNA replication and transcription49.”
From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredIn the citing paper
“Irinotecan exerts a cytotoxic effect by inhibiting DNA replication and transcription by targeting topoisomerase 1 (TOP-1) [87].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Self-citationVauthey, J.-N., Pawlik, T. M., Ribero, D., Wu, T.-T., Zorzi, D., Hoff, P. M., Xiong, H. Q., Eng, C., Lauwers, G. Y., Mino-Kenudson, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3074 · Cited by 1,300
Cited by
Items 201–266 of 266
Sirirak, T., & Subongkot, T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081014 · Cited by 1
“Irinotecan, a camptothecin-derivative anticancer drug, has been used for the treatment of various malignancies because it inhibits the topoisomerase I enzyme [17].”
Park, J., Bae, S. H., Jeon, S., Park, Y. H., Lee, D. C., & Han, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1556618 · Cited by 1
Singh, N. K., Awasthi, P., Gupta, A., Anand, N., Giri, B. S., & Hasan, S. (2025) · Biology · doi:10.3390/biology14091174 · Cited by 2
“The topoisomerase I inhibitor Irinotecan (IRN), which has the potential to treat solid tumours such as metastatic lung and colorectal cancer, was chosen as a decreased chemotherapeutic drug [17,18].”
Zhang, H., Hu, R.-H., Zhang, K.-H., Cui, X., & Zhang, S. (2025) · iScience · doi:10.1016/j.isci.2025.114199 · Cited by 1
“6,7 High intra-tumoral CES2 expression is desirable for therapeutic efficacy, a concept strongly supported by survival data in pancreatic cancer.”
Xia, C., Liu, J., Ren, Z., & Cao, Z. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04247-2 · Cited by 1
“This metabolite stabilizes the topoisomerase I–DNA cleavable complex, leading to irreversible DNA single-strand breaks and subsequent apoptosis [1–3].”
Cillari, R., Torres-Rodríguez, J., Sciré, S., Pérez‐Camargo, R. A., Roscigno, G., Müller, A. J., & Mauro, N. (2026) · European Polymer Journal · doi:10.1016/j.eurpolymj.2026.114747 · Cited by 1
Wang, L., Zhong, S., Zhao, J., Liu, L., & Li, C. (2026) · Cells · doi:10.3390/cells15121073 · Cited by 2
“It also elucidates the key mechanisms underlying tumour cell resistance to the active metabolite ethyl-10-hydroxy-s-n-38 (SN-38) [82]. https://doi.org/10.3390/cells15121073 4.5.”
InfluentialAdvanced biomaterial strategies for 3D in vitro biomimetic neuroblastoma cell culture
Thibieroz, N., Picart, C., & Migliorini, E. (2026) · Biomaterials Science · doi:10.1039/d6bm00438e · Cited by 1
Insight into the preclinical studies of phytomedicines in cancer theragnostics
KUMAR, A., Pramanik, J., Rustagi, S., Bharti, S., TREHAN, A., Katyal, M., Thakur, S., Haque, S., Bora, J., Kishore, S., et al. (2023) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.23.02968-1 · Cited by 1
Unveiling therapeutic avenues targeting xCT in head and neck cancer
Lee, J., & Roh, J. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00997-9 · Cited by 2
Rawat, J., Kachhadiya, R., & Thakkar, H. P. (2025) · Therapeutic Delivery · doi:10.1080/20415990.2025.2460421 · Cited by 1
Sharma, M., Dande, P. R., Saraf, A., Gawad, J., Maheshwari, R., & Ashique, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305906125010015 · Cited by 1
Jakac, M., Karačonji, I. B., Jurič, A., Lušić, D., Milinčić, D. D., Dramićanin, A., Pešić, M. B., Landeka, N., & Kopjar, N. (2025) · Toxics · doi:10.3390/toxics13030194 · Cited by 1
Tang, Z., Bi, R., Idriss, M., Wang, Q., Wang, Q., & Ban‐Hoefen, M. (2025) · Cancer Reports · doi:10.1002/cnr2.70276 · Cited by 1
Batool, S., Ishrat, G., Mustapha, O., Alamri, A. H., Fatease, A. M. A., Asiri, Z. A., Awadh, A. A. A., Choi, H., & Din, F. U. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00783-1 · Cited by 3
“Acute diarrhea may result from activation of the cholinergic system through acetylcholinesterase inhibition or accumulation of IRT metabolites in the bowel, resulting in delayed diarrhea (Kciuk et al. 2020).”
Nucleic Acids Conjugates for Biotechnological Applications
Endoh, T., Rozners, E., & Ohtsuki, T. (2021) · MDPI eBooks · doi:10.3390/books978-3-0365-1513-7
Chemoresistance in Colorectal Malignancies: Molecular Mechanisms and Strategies to Overcome.
Verma, H. K., Ratre, Y. K., & Mazzone, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-72702-4_7 · Cited by 1
Sacituzumab govitecan: a new antibody-drug conjugates in the cancer treatment landscape
Cai, Y., Ma, Y., Ren, S., & Zhao, S. (2022) · International Conference on Biotechnology, Life Science and Medical Engineering (BLSME) · doi:10.23977/blsme.2022040
“Topo I is an enzyme that corrects DNA serial numbers by cutting off the phosphate diester bond in one or both strands of DNA and then rewrapping and sealing it [4].”
BackgroundPark, W., O'Connor, C. A., Bandlamudi, C., Forman, D., Chou, J. F., Umeda, S., Reyngold, M., Varghese, A. M., Keane, F., Balogun, F. O., et al. (2023) · doi:10.1158/1078-0432.c.6532713
Pharmacotherapy of small cell lung cancer: Current state-of-the-art
Berezhnova, T. A., Lunyova, Y. A., Dyadina, K. S., & Borisov, V. A. (2023) · Research Results in Pharmacology · doi:10.18413/rrpharmacology.9.10001
“The ternary DNA complex irinotecan-topoisomerase I-nick prevents the release of topoisomerase (Kciuk et al. 2020).”
BackgroundRitu, R., Chandra, P., & Das, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3040606/v1
Ugrappa, S., Fuloria, N. K., Lalitha, P., Ravichandran, M., Noor, S. N. F. M., Solyappan, M., Khor, G. H., Sa’ad, M. A., Jain, A. K., Wu, Y. S., et al. (2023) · Asian Journal of Chemistry · doi:10.14233/ajchem.2023.28057
Zhou, Y., Gao, Y., Zhou, H., Fu, Y., Lin, Z., Shang, Y., Peng, S., Yang, C., & Ke, C. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4603279
Zhou, Y., Gao, Y., Zhou, H., Fu, Y., Lin, Z., Shang, Y., Peng, S., Yang, C., & Ke, C. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4611835 · Cited by 1
Chen, Y., Zhao, T., Miao, Z., Huang, T., Chen, M., Zhao, Y., Hai, A., Qi, Q., Feng, P., Li, M., et al. (2023) · The Analyst · doi:10.1039/d3an01745a
Gartel, A. L., Raghuwanshi, S., Zhang, X., Arbieva, Z. H., Khan, I., Wang, Z., Dömling, A. S. S., & Camacho, C. J. (2023) · Research Square · doi:10.21203/rs.3.rs-3711759/v1
“Taxanes (Paclitaxel or Docetaxel) are another class of antitumor drugs, that have been traditionally used in esophageal cancer treatment [45, 47].”
Background(2024) · Research Square · doi:10.21203/rs.3.rs-3711759/v2
Hassani, S., Malekinejad, H., Ansari, M. H. K., Abbasi, A., & Kheradmand, F. (2024) · Preprints.org · doi:10.20944/preprints202401.2037.v1
Singh, V. V., Punia, A., Gupta, S., Thakur, A., Kumar, R., & Chauhan, N. S. (2023) · Reference series in phytochemistry · doi:10.1007/978-3-031-21973-3_58-1
Zhou, Y., Gao, Y., Zhou, H., Fu, Y., Wu, H., Lin, Z., Shang, Y., Peng, S., Yang, C., & Ke, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4750450
In vitro evaluation of novel SN-38 prodrug activated by α-rhamnosidase of exogenous enzyme
Nii, T., Hijii, S., Kaneko, R., Tanito, K., Yamanaka, K., Kishimura, A., Mori, T., & Katayama, Y. (2024) · Analytical Sciences · doi:10.1007/s44211-024-00593-9
“Third, SN-38 causes severe side effects, especially delayed diarrhea (intestinal mucositis) due to the endogenous hCE1 [11].”
Iliev, I. A., Tsoneva, I. C., Nesheva, A., Staneva, G., Robev, B., Momchilova, A., & Nikolova, B. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46110740
“The drug is predominately used for colorectal cancer cells [13,21].”
Understanding colorectal cancer, screening, and treatment
Ghanta, M. K., Hussain, M. F., Kurumella, S. N. D., Chenchula, S., Kumar, N. N., Malla, M., & Bhaskar, L. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00009-5
Systemic therapies for localized colon cancer and metastatic colorectal cancer
Platt, J. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29048-0.00002-1
Wieduwilt, F., Geweke, J., Merker-Müller, F., Linxweiler, H., Heeb, R. M., Ctistis, G., & Wackerbarth, H. (2025) · Optical Diagnostics and Sensing: Toward Point-of-Care Diagnostics · doi:10.1117/12.3043812
“It is primarily used in treating metastatic colorectal cancer and is also used off-label for small-cell lung cancer [16].”
Newly acylated SN-38 homodimers: carrier-free nano-prodrugs for chemotherapy
Kumar, S., Koseki, Y., Tanita, K., & Kasai, H. (2025) · Mendeleev Communications · doi:10.71267/mencom.7664
Role of dePEGylation in vesicular carriers-mediated stimuli-responsive drug delivery to tumors
Vikal, A., Maurya, R., Vashishat, A., Singh, T., Khare, S., Patel, P., & Kurmi, B. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29125-8.00003-x
PATAMSETTI, A., & Gubbiyappa, K. S. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i3.53698
He, Y., Xu, H., Tan, S., Long, J., Lei, H., Ling Zhi, X. I. A. O., Qi, X., Deng, M., Xiong, X., You, J., et al. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2501041
“…docking assays reveal that the c7-hydroxyl group on the a-ring does not participate in molecular interactions with either enzyme (Figures 8 and 9), contrasting sharply with established structure–activity relationship paradigms for flavone inhibitors. in flavone derivatives, retention of…”
InfluentialDilber, T., Yalçın, G. D., Yilmaz, K. C., & Acar, A. (2025) · FEBS Letters · doi:10.1002/1873-3468.70208
Clinically actionable UGT1A1 variants in black Zimbabwean cancer patients eligible for irinotecanPreprint
Wesonga, R. M., Mazhindu, T. A., Chikwambi, Z., Borok, M. Z., Ndlovu, N., Polasek, T. M., & Masimirembwa, C. M. (2025) · doi:10.12688/verixiv.2312.1
A patent review of topoisomerase 1 inhibitors (2021–present)
Fuertes, M., Martín‐Encinas, E., Selas, A., & Alonso, C. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2579073
Additional file 1 of Single protein encapsulated SN38 for tumor-targeting treatment
Yu, C., Huang, F., Wang, K., Liu, M. C., Chow, W. A., Ling, X., Fengzhi, L. I., Causey, J., Huang, X., Cook‐Wiens, G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24784608
Nagi, R., Ozukum, A., Mondal, R., & Deb, C. R. (2026) · Journal of Experimental Biology and Agricultural Sciences · doi:10.18006/2026.14(1).44.54
Saha, V., Hossain, A., Miraj, K. Z., Sepay, N., Sarkar, S., Roy, S., Im, J., & Biswas, G. G. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118553
Shao, Y., Zhang, Z., Wang, Y., Zhang, C., Liu, E., & Yu, H. (2026) · Targetome · doi:10.48130/targetome-0025-0012
Li, Y., Li, S. X., Li, Y., & Pan, Z. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121430
Thakur, N., Mota-Santiago, P., Shuddhodana, & Judeh, Z. M. A. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115601
Wang, X., He, M., Han, X., Peng, M., Wang, T., & Wang, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109765
Rahman, I., Meda, A., Moore, K. A., Sajid, A., Ambudkar, S. V., & Huang, H. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70136
“45”
Watanabe, S., Mori, N., Toyooka, S., Utsunomiya, K., Kurokawa, Y., Nakagami, Y., & Yamaguchi, T. (2026) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b26-00018
PATAMSETTI, A., & Gubbiyappa, K. S. (2026) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902026e24587
Phytochemistry and Pharmacology of Mappia : Research and Development
Ameen, N., Shahbaz, M., Ahmad, F., Ahmad, M. S. A., & Sharma, T. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813031126050007
Parhi, P., Banerjee, A., & Thatoi, H. (2026) · Journal of Chemotherapy · doi:10.1080/1120009x.2026.2653339
Xiang, M., Zhou, C., Yao, C., Liu, J., Wang, L., & Wang, Z. (2026) · ACS Nano · doi:10.1021/acsnano.6c00855 · Cited by 1
Medrano-Villagómez, C., Loredo-García, E., Gasperin-Bulbarela, J., & Vázquez-Duhalt, R. (2026) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s576292
“33 The cytotoxicity of irinotecan in two human colorectal tumor cell lines, LoVo and HT-29, showed IC 50 values of 15.8 µM and 5.17 µM, respectively, 11 which are significantly higher than those found (0.18 µM) on the MOLT-4 cell line (Table 1).”
InfluentialZhao, Y. J., Jin, Y., Fu, L., Yao, D., Zhou, Z., Dong, Y., & Tan, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1798282
Lu, J., Huang, Y., Ma, S., Hu, S., Xuzhan, L., Huang, Y., Wu, B., Hu, Z., Zhao, C., Huang, J., et al. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02185-5
“PTX [27], CDDP [28], CTP-11 [29], and GEM [30 ] are all classic first-line clinical chemother - apy drugs [29, 31].”
Irinotecan-induced Neutropenia: A Comprehensive Review of Pathogenesis, Risk Factors, and Management
Zhang, L., Tian, C., Li, W., Yan, L., Shu, C., & Zhang, C. (2026) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2026.00002
Biltekin, B., & Çetin, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135814
“The conventional antitumor agent irinotecan, a topoisomerase I inhibitor, has been applied to various cancer types, including glioma and is known to cross the BBB [8,9].”
Zhang, Y., Cao, X., Hou, Z., Liu, Z., & Liu, S. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117676
Clinical Implications of UGT1A1 Polymorphisms in Anticancer Therapy: An Updated Review
Vitale, S. R., Drago, M., Martorana, F., Conti, C., Massimino, M., Stella, S., Tomarchio, C., Vigneri, P. G., & Manzella, L. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080928
“Glucuronidation increases solubility and facilitates SN-38 excretion into the bile and then the urine [29].”
Risk factors for irinotecan-induced hepatotoxicity: a retrospective cohort study
Alherz, F. A., Alnakhli, A. M., Alqarni, A. M., Alshammari, A. F., Ruwayi, A. M., Alyamani, R. M., Al-salloum, H., Al‐Yamani, M., & Shuweihdi, F. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1777922
Lozano-García, M., Vogiatzis, C., Planells‐Devesa, A., Dikici, E., Maluf, C. V., Nayak, V. V., Coelho, P. G., Witek, L., Bilbao, A., Bilbao, D., et al. (2026) · Advanced Functional Materials · doi:10.1002/adfm.77242
“…(SN-38), the active metabolite of irinotecan, is a potent topoisomerase I inhibitor widely used for the treatment of lethal malignancies, such as colorectal, pancreatic, lung, breast, gastric, esophageal, hepatocellular, ovarian, brain, leukemia, and lymphoma cancers [ 7, 8 ].”
The Double-Edged Role of Enzyme Inhibition in Oral Anticancer Therapy
Assiri, A. A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101251
Lauro, V. D., Sacco, P. C., Palma, V., von Arx, C., Buono, G., Caputo, R., Piezzo, M., Cocco, S., Vitale, E., Santoni, M., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2743869
Metadata
- Authors
- Kciuk, M., Marciniak, B., & Kontek, R.
- Affiliations
- University of Łódź (PL)
- Corresponding author
- Kciuk, Mateusz
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-12
- Volume
- 21
- Issue
- 14
- Pages
- 4919
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7404108
- OpenAlex
- W3041813955
- Cited by
- 266
- References
- 136
- Citations by year
- 2026: 29 · 2025: 76 · 2024: 66 · 2023: 50 · 2022: 29 · 2021: 13 · 2020: 3
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, SN-38, pharmacogenetics, drug metabolism, drug toxicity, combination chemotherapy, liposomal formulation, dendrimers, nanoparticles, drug resistance, anticancer agents
- MeSH terms
- Irinotecan, Antineoplastic Combined Chemotherapy Protocols, DNA, Neoplasm, Dosage Forms, Drug Compounding, Drug Synergism, Female, Humans, Male, Models, Molecular, Neoplasm Proteins, Neoplasms, Nucleic Acid Conformation, Prodrugs, Protein Conformation, Molecular Structure, Drug Resistance, Neoplasm, Polymorphism, Single Nucleotide, Topoisomerase I Inhibitors, Activation, Metabolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.